MARKET

CMPX

CMPX

Compass Therapeutics Inc
NASDAQ
2.945
-0.015
-0.51%
After Hours: 2.990 +0.045 +1.53% 18:28 06/02 EDT
OPEN
3.000
PREV CLOSE
2.960
HIGH
3.000
LOW
2.900
VOLUME
392.10K
TURNOVER
0
52 WEEK HIGH
5.65
52 WEEK LOW
1.810
MARKET CAP
372.56M
P/E (TTM)
-8.1129
1D
5D
1M
3M
1Y
5Y
SVB Securities Keeps Their Buy Rating on Compass Therapeutics (CMPX)
TipRanks · 05/09 10:55
Compass Therapeutics GAAP EPS of -$0.06
Seeking Alpha · 05/04 17:22
H.C. Wainwright Reaffirms Their Buy Rating on Compass Therapeutics (CMPX)
TipRanks · 05/04 14:15
Compass Therapeutics: Q1 Earnings Insights
Benzinga · 05/04 13:36
BRIEF-Compass Therapeutics Inc Ended Q1 With $175 Million In Cash And Marketable Securities
Reuters · 05/04 12:34
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 04/26 13:06
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 04/21 13:06
SVB Securities Remains a Buy on Compass Therapeutics (CMPX)
TipRanks · 03/20 13:47
More
About CMPX
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is focused on developing proprietary antibody-based therapeutics to treat multiple human diseases. The Company’s pipeline is comprised of three product candidates, such as CTX-009, CTX-471, and CTX-8371. The Company’s lead product candidate, CTX-009, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). The Company’s second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor and its ligand PD-L1, two validated immune-oncology targets.

Webull offers kinds of Compass Therapeutics Inc. stock information, including NASDAQ:CMPX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CMPX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CMPX stock methods without spending real money on the virtual paper trading platform.